The FDA is keeping its cards close to the vest when it comes to the potential approval of a booster dose of Moderna’s COVID-19 vaccine.
On Sept. 3, Moderna originally applied for emergency use authorization for a booster for everyone over the age of 12.is not yet authorized for children and teens 12 to 18, and after Pfizer’s bid to give boosters to teens failed, the company revised its request for authorization.
Moderna is now asking the FDA to approve a 50 mg booster, which is half the dose of the original shots, for everyone over the age of 65, and for those ages 18 to 64 who are at greater risk of COVID-19 because of an underlying health condition or who are exposed to the virus frequently at work.The most commonly reported negative reactions after the Moderna booster were mild, and included
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
U.S. FDA staff says Moderna did not meet all criteria for COVID-19 boostersScientists at the U.S. Food and Drug Administration said on Tuesday that Moderna Inc had not met all of the agency's criteria to support use of booster doses of its COVID-19 vaccine, possibly because the efficacy of the shot's first two doses has remained strong.
Read more »
Merck asks the FDA to authorize use of its promising COVID-19 pillDrugmaker Merck has asked U.S. regulators to authorize its promising pill protecting against COVID-19, setting the stage for a decision within weeks.
Read more »
Merck asks FDA to authorize antiviral Covid pill for emergency useMerck has asked the FDA to authorize its antiviral Covid pill for emergency use. ScottGottliebMD weighs in: 'I think where the government misstepped is that we didn't invest enough in trying to scale up the manufacturing of therapeutics across the board.'
Read more »
Merck Seeks FDA Authorization for Antiviral COVID-19 PillDrugmaker Merck announced Monday that it submitted an application to the FDA for emergency use authorization of molnupiravir, an experimental antiviral COVID-19 treatment.
Read more »
Merck asks US FDA to authorize promising anti-COVID pillWASHINGTON (AP) — Drugmaker Merck asked U.S. regulators Monday to authorize its pill against COVID-19 in what would add an entirely new and easy-to-use weapon to the world's arsenal against the pandemic.
Read more »